secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2026-11-10T20:50:16+00:00
Accession:  0001193125-26-455339
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Exicure to sell GPC-100 (burixafor) assets to Korea's GPCRT for KRW 6.5B (~US$4.8M)
--------------------------------------------------------------------------------

- Aggregate cash price KRW 6.5B (~US$4.8M): KRW 500M deposit already paid and credited, KRW 2.0B due by November 16, 2026, KRW 4.0B at closing.
- Assets: rights under the January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, plus IP, clinical/regulatory data, materials and equipment.
- GPCRT assumes post-closing obligations including future milestone and royalty payments to GPCR, and bears GPC-100 program costs incurred on or after September 1, 2026.
- GPC-100 was evaluated with propranolol for stem cell mobilization in multiple myeloma; GPCR USA completed its Phase 2 trial in January 2026.
- Closing needs board approvals, regulatory and third-party consents, a GPCR waiver/release, and any required Exicure stockholder approval; timing not assured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/0001193125-26-455339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000119312526455339/xcur-20261104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer